Aptus Pharma Limited has formally notified the BSE about an upcoming board meeting scheduled for April 27, 2026, where directors will deliberate on the company's audited financial results for the year ended March 31, 2026. The pharmaceutical company made this announcement on April 20, 2026, in compliance with regulatory requirements under SEBI listing obligations.

Board Meeting Details

The meeting agenda includes consideration and approval of the company's audited financial results for the year ended March 31, 2026. Additionally, the board will take on record the auditor's report accompanying these financial results.

Trading Window Closure

In accordance with the company's Code of Conduct for Prohibition of Insider Trading and SEBI regulations, Aptus Pharma has implemented a trading window closure. The trading window for dealing in the company's securities has been closed and will remain closed until 48 hours after the declaration of the financial results.

Regulatory Compliance

The notification was issued pursuant to Regulation 29(1)(a) read with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Managing Director Tejash Maheshchandra Hathi, bearing DIN 03151221, signed the official communication to BSE Limited on April 20, 2026.

Company Information

Aptus Pharma Limited operates from its registered address in Ahmedabad, Gujarat, and trades on BSE under scrip code 544529. The company maintains its corporate presence in the pharmaceutical sector with established communication channels for investor relations and regulatory compliance.

Aptus Pharma Limited has filed its mandatory compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018 for the half year ended March 31, 2026. The pharmaceutical company submitted the certificate to BSE Limited on April 11, 2026, fulfilling its regulatory obligations for the reporting period.

Regulatory Compliance Details

The certificate covers the period from January 1, 2026 to March 31, 2026, and was prepared by Accurate Securities & Registry Private Limited, which serves as Aptus Pharma's Registrar and Share Transfer Agent. The compliance filing confirms adherence to SEBI regulations governing dematerialisation processes and depositories.

Certificate Confirmation

Accurate Securities & Registry Private Limited confirmed that all securities received from depository participants for dematerialisation during the specified period were processed within the stipulated time limits as required under SEBI regulations. The registrar verified that securities were either accepted or rejected on technical grounds as appropriate, and all processes were completed in compliance with regulatory requirements.

The certificate also confirms that securities received for dematerialisation were properly mutilated and cancelled after due verification, following operational procedures. Additionally, the names of depositories were substituted in the security holder's list as registered owners within the prescribed time limits.

Company and Registrar Information

Tejash Hathi, Managing Director of Aptus Pharma Limited (DIN: 03151221), signed the submission letter to BSE. Accurate Securities & Registry Private Limited, registered with SEBI under registration number INR000004173, operates from its registered office in Ahmedabad and maintains working hours from Monday to Friday, 11.30 AM to 5.00 PM with a lunch break from 1.30 PM to 2.30 PM.

This regulatory filing demonstrates Aptus Pharma's commitment to maintaining compliance with SEBI regulations and ensuring proper handling of dematerialisation processes through its appointed registrar and share transfer agent.